Andrew Gengos, Chief Financial Officer at Terns Pharmaceuticals, Inc. (TERN), bought 5,000 shares at $3.93 ($20K) on 2025-06-27, disclosed to the SEC on 2025-06-30.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| ATHA | SELL | 2024-02-16 | $4K | — | Filing → |
| ATHA | SELL | 2024-01-08 | $4K | — | Filing → |
| ATHA | BUY | 2023-06-09 | $51K | — | Filing → |